Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

TEMPISIN1234
Filter zurücksetzen
Fr., 25.10.2024

NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- WeRide Inc. (“WeRide” or the “Company”) (Nasdaq: WRD), a global leader and a first mover in the autonomous driving industry, today announced the pricing of its initial public offering of 7,742,400 American depositary shares (“ADSs”), each representing three Class A ordinary shares of the Company, at a p...
Fr., 25.10.2024

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the pricing of its upsized initial public offering of 16,000,000 shares of its common stock at a public o...
Mo., 21.10.2024

MAREX GROUP PLC ANNOUNCES LAUNCH OF A PUBLIC OFFERING...
Di., 15.10.2024

WeRide's new generation production Robotaxi GXR, the world's most spacious production Robotaxi model to date....
Fr., 11.10.2024

Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the Company’s abstract “Varog...
Mi., 09.10.2024

Marex agrees terms to acquire UK FX specialist Hamilton Court Group...
Mi., 02.10.2024

MAREX EXPANDS IN THE MIDDLE EAST WITH THE ACQUISITION OF AARNA CAPITAL...
Di., 01.10.2024

MAREX ACQUIRES BIOFUELS COMPANY DROPET...
Di., 01.10.2024

Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced key takeaways from its virtual Kidn...
Do., 26.09.2024

Key Carbon & Marex Group Announce Carbon Financing and Investment...
Silent Ad
Do., 26.09.2024

RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the pricing of its upsized initial public offering of 11,000,000 shares o...
Do., 12.09.2024

GDEV Announces an At-The-Market Offering...
Do., 12.09.2024

Mi., 11.09.2024

SAN DIEGO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, and Jam...
Fr., 06.09.2024

Marex Group plc to participate in upcoming Barclays Global Financial Services Conference...
Do., 05.09.2024

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association...
Do., 05.09.2024

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024...
Mi., 04.09.2024

GDEV announces unaudited results for the second quarter and first half of 2024...
Mi., 21.08.2024

GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company, announced a one-for-ten (1:10) reverse share split of its ordinary shares....
Mi., 14.08.2024

Marex Group plc announces 2024 Interim Results...
Silent Ad
Fr., 19.07.2024

MAREX GROUP PLC PROVIDES NOTICE OF H1 2024 RESULTS AND CONFERENCE CALL...
Do., 18.07.2024

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease...
Di., 16.07.2024

MAREX OPENS NEW ZEALAND OFFICE...
Di., 09.07.2024

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease...
Fr., 21.06.2024

Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting...
Di., 18.06.2024

LONDON, June 18, 2024 (GLOBE NEWSWIRE) -- Marex Group Plc (NASDAQ: MRX), the diversified global financial services platform, has appointed Liz Barrett as Group Head of HR. Liz joins on June 24, and brings over twenty years of experience in financial services. Liz replaces Karen Neffar who leaves Marex to pursue personal interests and other projec...
Mo., 17.06.2024

Marex to offer client clearing of interest rate swaps...
Do., 13.06.2024

Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling...
Fr., 31.05.2024

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- Marex Group plc (‘Marex’ or the ‘Group’), a diversified global financial services platform, today announces that it will be hosting a fireside chat at Piper Sandler's Global Exchange & FinTech Conference. The presentation will be given by Ian Lowitt, Group Chief Executive Officer and will take place...
Di., 28.05.2024

GDEV announces preliminary unaudited results for the first quarter 2024...
Do., 23.05.2024

Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease...
Do., 16.05.2024

NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Marex Group plc (‘Marex’ or the 'Group’), a diversified global financial services platform, announces strong results for the twelve months ended December 31, 2023, and a positive update for the first three months ended March 31, 2024....
Mi., 15.05.2024

Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024...
Mo., 13.05.2024

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Marex Group (“Marex”), the diversified global financial services platform, will announce its full year 2023 results and first quarter 2024 update on May 16, 2024, before market open. The earnings release and supplementary materials will be available on the Marex website at https://ir.marex.com/....
Mi., 08.05.2024

Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024...